argenx SE (EBR:ARGX)

Belgium flag Belgium · Delayed Price · Currency is EUR
723.60
+11.80 (1.66%)
Oct 20, 2025, 3:59 PM CET
1.66%
Market Cap43.56B
Revenue (ttm)2.66B
Net Income (ttm)1.09B
Shares Out61.20M
EPS (ttm)15.96
PE Ratio44.59
Forward PE40.25
Dividendn/a
Ex-Dividend Daten/a
Volume22,762
Average Volume80,562
Open723.60
Previous Close711.80
Day's Range718.80 - 733.80
52-Week Range456.60 - 731.80
Beta0.04
RSI75.23
Earnings DateOct 30, 2025

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 1,599
Stock Exchange Euronext Brussels
Ticker Symbol ARGX
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

argenx Reaches Analyst Target Price

In recent trading, shares of argenx SE (Symbol: ARGX) have crossed above the average analyst 12-month target price of $826.86, changing hands for $837.28/share. When a stock reaches the target an anal...

3 days ago - Nasdaq

argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session

Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART's potential to treat broad set of myasthenia gravis patients Real-world evidence and long-term data reinforce VYVGART's sustained...

5 days ago - GlobeNewsWire

How Do Investors Really Feel About argenx SE?

argenx SE's (NYSE: ARGX) short interest as a percent of float has fallen 4.76% since its last report. According to exchange reported data, there are now 1.67 million shares sold short , which is 3.0%...

6 days ago - Benzinga

Wedbush Raises Price Target for ARGX, Maintains Outperform Rating | ARGX Stock News

Wedbush Raises Price Target for ARGX, Maintains Outperform Rating | ARGX Stock News

7 days ago - GuruFocus

argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025

October 3, 2025 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, toda...

16 days ago - GlobeNewsWire

Morgan Stanley Raises Price Target for ARGX to $1040 While Maintaining Overweight Rating | ARGX ...

Morgan Stanley Raises Price Target for ARGX to $1040 While Maintaining Overweight Rating | ARGX Stock News

18 days ago - GuruFocus

INCY vs. ARGX: Which Stock Is the Better Value Option?

INCY vs. ARGX: Which Stock Is the Better Value Option?

19 days ago - Nasdaq

Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today

argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 7.61% on an annualized basis producing an average annual return of 22.36%. Currently, argenx has a market capitalization of ...

21 days ago - Benzinga

Price Over Earnings Overview: argenx

In the current market session, argenx Inc. (NASDAQ: ARGX) share price is at $711.62, after a 0.07% increase. Moreover, over the past month, the stock decreased by 0.08% , but in the past year, went u...

23 days ago - Benzinga

Guggenheim Reiterates Buy Rating for ARGX with Target Price of $1070 | ARGX Stock News

Guggenheim Reiterates Buy Rating for ARGX with Target Price of $1070 | ARGX Stock News

4 weeks ago - GuruFocus

FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations

HOLLY SPRINGS, N.C.--(BUSINESS WIRE)--FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, today announced a s...

4 weeks ago - Business Wire

argenx SE - Special Call

4 weeks ago - Seeking Alpha

argenx SE (ARGX) Special Call - Slideshow

2025-09-16. The following slide deck was published by argenx SE in conjunction with this event.

4 weeks ago - Seeking Alpha

ARGX Quantitative Stock Analysis - Benjamin Graham

Below is Validea's guru fundamental report for ARGENX SE - ADR (ARGX). Of the 22 guru strategies we follow, ARGX rates highest using our Value Investor model based on the published strategy of Benjami...

4 weeks ago - Nasdaq

argenx: Bullish On This R&D Focused Biotech Stock

argenx's blockbuster Vyvgart drives rapid growth, but heavy reliance on one product and US sales creates concentration risk. The company's robust R&D investment and Immunology Innovation Program fuel ...

5 weeks ago - Seeking Alpha

Deutsche Bank Downgrades Argenx (ARGX) Rating Amid Valuation Concerns

Deutsche Bank Downgrades Argenx (ARGX) Rating Amid Valuation Concerns

5 weeks ago - GuruFocus

$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today

argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 12.84% on an annualized basis producing an average annual return of 26.74%. Currently, argenx has a market capitalization of...

5 weeks ago - Benzinga

Is argenx Gaining or Losing Market Support?

argenx's (NYSE: ARGX) short percent of float has fallen 4.11% since its last report. The company recently reported that it has 1.81 million shares sold short , which is 3.27% of all regular shares th...

5 weeks ago - Benzinga

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.

6 weeks ago - CNBC Television

B of A Securities Raises Price Target on ARGX to $887 | ARGX Stock News

B of A Securities Raises Price Target on ARGX to $887 | ARGX Stock News

6 weeks ago - GuruFocus

argenx to Present at Upcoming Investor Conferences

August 28, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today a...

7 weeks ago - GlobeNewsWire

Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded

Argenx saw its IBD SmartSelect Composite Rating rise to 96 Tuesday, up from 94 the day before.

7 weeks ago - Investor's Business Daily

Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win

Argenx SE (NASDAQ: ARGX) stock is trading higher on continued upward momentum after the company released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: efgartigimod...

7 weeks ago - Benzinga